Clinical Updates – Page 21

Abbreviated Romosozumab Regimens in Postmenopausal Osteoporosis: A Review of the LIDA Trial and the Shift Toward Precision Anabolic Dosing

By MedXY 03/09/2026

This review evaluates the LIDA trial's findings that 3 months of romosozumab followed by denosumab is non-inferior to 12 months of romosozumab, offering a cost-effective strategy to mitigate long-term side effects.

Clinical Updates Neurology news

Precision Rehabilitation for Chronic Stroke: Validating Targeted Ipsilesional Arm Training to Enhance Functional Capacity

By MedXY 03/09/2026

A pivotal randomized clinical trial reveals that targeted training of the ipsilesional arm in chronic stroke patients with severe hemiparesis significantly improves motor speed and hand function, with benefits sustained for six months.

Clinical Updates Diabetes & Endocrinology news OB/GYN & Women's Health

Management of Graves’ Disease During Pregnancy: Clinical Insights from the Danish PRETHYR Multicenter Study

By MedXY 03/09/2026

This clinical review synthesizes findings from the PRETHYR study on antithyroid drug use in pregnant women, highlighting treatment transitions, biochemical predictors, and the impact of specialist-led management in Denmark.

Clinical Updates Diabetes & Endocrinology news

Transitioning to Tubeless Automated Insulin Delivery: Clinical Insights from the RADIANT Trial and Contemporary Management of Type 1 Diabetes

By MedXY 03/09/2026

This review synthesizes the landmark RADIANT trial findings, demonstrating the efficacy of transitioning patients from multiple daily injections to tubeless automated insulin delivery, while integrating broader evidence on genetic susceptibility and metabolic comorbidity management.

AI Cardiology Clinical Updates news

Precision Prediction of Incident Heart Failure: The Clinical Integration of AI-Enabled Electrocardiography

By MedXY 03/09/2026

This review evaluates the breakthrough ECG2HF model, a publicly available AI tool that outperforms standard clinical scores in predicting 10-year heart failure risk using 12-lead ECG waveforms.

Cardiology Clinical Updates news

Genotype-Phenotype Divergence in Hypertrophic Cardiomyopathy: Deciphering the Trajectories of Sarcomeric and Nonsarcomeric Disease

By MedXY 03/09/2026

This review analyzes the SHaRe registry data, revealing that sarcomeric HCM represents a more aggressive clinical phenotype with earlier onset and higher HCM-related mortality compared to nonsarcomeric cases, which are more heavily influenced by modifiable metabolic comorbidities.

Clinical Updates Infectious Diseases news

Potent Inhibition of Hepatitis E Virus Replication by Bemnifosbuvir: Preclinical Evidence and Clinical Prospects

By MedXY 03/08/2026

Preclinical studies demonstrate that the nucleotide analogue bemnifosbuvir effectively suppresses Hepatitis E virus (HEV) replication, showing synergistic potential with ribavirin and a high genetic barrier to resistance.

Clinical Updates Neurology news

Differential Pathophysiological Roles of Centrum Semiovale Perivascular Spaces in Cerebral Amyloid Angiopathy and Deep Perforator Arteriopathy: A Biomarker Synthesis

By MedXY 03/08/2026

This review synthesizes evidence distinguishing perivascular space enlargement mechanisms in cerebral amyloid angiopathy (CAA) versus deep perforator arteriopathy (DPA), highlighting the diagnostic utility of CSF Aβ42/40 ratios in vascular amyloid pathology.

Clinical Updates General Surgery news

Therapeutic Potential of Autologous Blood Derivatives in Tissue Regeneration: A Systematic Review of Clinical Evidence and Mechanistic Insights

By MedXY 03/08/2026

This review synthesizes recent PubMed-indexed evidence on autologous blood-derived therapies, such as PRP and PRF, highlighting their role in accelerating wound healing through growth factor signaling and cellular recruitment.

Clinical Updates Neurology news

Treatment Evolution in 5q-Spinal Muscular Atrophy: Real-World Evidence and Clinical Insights from the SMArtCARE Registry

By MedXY 03/08/2026

This review analyzes the shifting landscape of SMA therapy using data from 2,140 patients, highlighting the transition between nusinersen, risdiplam, and onasemnogene abeparvovec and the factors driving treatment switches.

Clinical Updates Neurology news Rheumatology

Mapping the Genomic Landscape of Multiple Sclerosis Across Diverse Ancestries: Insights into Shared and Population-Specific Susceptibility

By MedXY 03/08/2026

This study demonstrates that while MS genetic risk factors are largely shared across ancestral groups, their predictive power and population-level impact vary significantly between European, South Asian, and African populations.

Clinical Updates Neurology news

Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial and Synthesis of Emerging Neuroprotective Paradigms

By MedXY 03/08/2026

This review evaluates a recent 2-year pilot RCT on low-dose lithium carbonate for MCI, synthesizing its findings with emerging evidence on Aβ clearance, gut-brain axis modulation, and multimodal disease forecasting.

Clinical Updates news

Comparative Diagnostic Performance of Global Thyroid Ultrasound Risk Stratification Systems: The Impact of Nodule Size and Lexicon Standardization

By MedXY 03/08/2026

This review synthesizes findings from a large-scale comparison of five major thyroid ultrasound risk stratification systems (RSSs), evaluating how nodule size and standardized lexicon influence sensitivity, specificity, and unnecessary biopsy rates.

Clinical Updates news

Preventive PCI for Non-Flow-Limiting Vulnerable Plaques: Paradigm Shift or Preemptive Risk?

By MedXY 03/07/2026

This evidence-based review examines the debate over adding preventive PCI to medical therapy for vulnerable plaques, analyzing the PREVENT trial results and the role of intracoronary imaging in risk stratification.

Clinical Updates news

Beyond Traditional Risk Factors: Deconstructing the Burden of Coronary Atherosclerosis in Liver Transplant Recipients

By MedXY 03/07/2026

A landmark nationwide study reveals that liver transplant recipients face significantly higher prevalence and severity of coronary atherosclerosis and high-risk plaque compared to matched controls, independent of traditional cardiovascular risk factors.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.

Clinical Updates Neurology news

Age at Onset and Clinical Trajectory in AQP4-IgG NMOSD: Decoupling Relapse Risk from Disability Accrual

By MedXY 03/06/2026

This review analyzes how age at onset influences NMOSD, revealing that while relapse risk remains constant across age groups, older onset significantly accelerates disability progression, necessitating early high-efficacy therapy.

Clinical Updates Neurology news

Rethinking Rhythm Control for Secondary Stroke Prevention: Insights from the STABLED Randomized Clinical Trial

By MedXY 03/06/2026

This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.

Cardiology Clinical Updates news

Revisiting Pharmacotherapy in Nonobstructive Hypertrophic Cardiomyopathy: Insights from a Randomized Triple-Crossover Trial of Bisoprolol vs. Verapamil

By MedXY 03/06/2026

A pivotal triple-crossover RCT reveals that while bisoprolol reduces exercise capacity and worsens diastolic markers in nonobstructive HCM, verapamil maintains exercise performance and improves myocardial strain.

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Clinical Updates news Oncology

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY 03/06/2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial evidence.